Vincent O'Neill files SEC Form 4 disclosures for BioXcel Therapeutics, Inc.. They have made 4 open-market trades across 1 company since 2020, most recently 2024-12-16.
CIK 0001672718
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BTAI | 20,122 | $1K |
Shares reported on the most recent Form 4, priced at the 2024-12-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BTAI | SELL · 10b5-1 | 2024-12-16 | 2024-12-17 | $0.35 | $58 | -6.0% | -11.4% | -63.5% |
| BTAI | SELL · 10b5-1 | 2024-10-03 | 2024-10-03 | $0.55 | $3K | +3.4% | +17.3% | -28.7% |
| BTAI | SELL · 10b5-1 | 2024-09-16 | 2024-09-17 | $0.69 | $95 | -5.8% | -10.9% | -36.5% |
| BTAI | SELL · 10b5-1 | 2024-06-17 | 2024-06-18 | $1.29 | $200 | -3.3% | +2.5% | -47.1% |
| BTAI | SELL · 10b5-1 | 2024-04-04 | 2024-04-08 | $2.62 | $432 | -1.2% | -17.8% | -58.1% |
| BTAI | SELL · 10b5-1 | 2023-03-15 | 2023-03-16 | $19.70 | $17K | -7.4% | +12.3% | +11.3% |
| BTAI | SELL | 2023-01-20 | 2023-01-24 | $30.00 | $891K | -3.6% | -3.1% | -27.3% |
| BTAI | SELL | 2021-02-17 | 2021-02-19 | $55.65 | $2.6M | -13.9% | -15.5% | -42.4% |
| BTAI | SELL | 2021-01-19 | 2021-01-21 | $49.35 | $2.3M | +6.7% | +15.6% | -26.5% |
| BTAI | SELL | 2020-12-28 | 2020-12-30 | $51.45 | $2.6M | +6.8% | -5.8% | -16.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.